XML 31 R21.htm IDEA: XBRL DOCUMENT v3.25.3

Revenues (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of net product revenues by product

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2025 and 2024:

			Three months ended September 30,												Nine months ended September 30,
			2025						2024						2025						2024
Products:
Kristalose			$	1,180,934					$	3,632,258					$	7,419,832					$	10,935,702
Sancuso			3,240,947						2,607,558						8,616,353						6,624,102
Vibativ			2,598,454						1,028,013						6,678,374						5,087,983
Caldolor			867,013						1,271,252						3,762,746						3,586,199
Acetadote			96,597						21,374						441,503						144,973
Vaprisol			600						(135,765)						(14,621)						(128,684)
Omeclamox-Pak			(3,127)						(18)						(9,266)						(2,574)
RediTrex			4,434						36,950						7,330						71,350
Other revenue			306,510						624,204						3,940,529						1,113,325
Total net revenues			$	8,292,362					$	9,085,826					$	30,842,780					$	27,432,376

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration